Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al

Merel J l'Ami; Charlotte L M Krieckaert; Michael T Nurmohamed; Ronald F van Vollenhoven; Theo Rispens; Maarten Boers; Gerrit Jan Wolbink

doi:https://doi.org/10.1136/annrheumdis-2017-212602

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al

Merel J l'Ami, Charlotte L M Krieckaert, Michael T Nurmohamed, Ronald F van Vollenhoven, Theo Rispens, Maarten Boers, Gerrit Jan Wolbink

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Original language	English
Article number	e68
Pages (from-to)	e68
Journal	Annals of the rheumatic diseases
Volume	77
Issue number	10
Early online date	13 Nov 2017
DOIs	https://doi.org/10.1136/annrheumdis-2017-212602
Publication status	Published - Oct 2018

Keywords

Journal Article

Access to Document

https://doi.org/10.1136/annrheumdis-2017-212602

Cite this

l'Ami, M. J., Krieckaert, C. L. M., Nurmohamed, M. T., van Vollenhoven, R. F., Rispens, T., Boers, M., & Wolbink, G. J. (2018). Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al. Annals of the rheumatic diseases, 77(10), e68. Article e68. https://doi.org/10.1136/annrheumdis-2017-212602

l'Ami, Merel J ; Krieckaert, Charlotte L M ; Nurmohamed, Michael T et al. / Response to : Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al. In: Annals of the rheumatic diseases. 2018 ; Vol. 77, No. 10. pp. e68.

@article{4e81ba75279b415eb703638e87354ec2,

title = "Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al",

keywords = "Journal Article",

author = "l'Ami, {Merel J} and Krieckaert, {Charlotte L M} and Nurmohamed, {Michael T} and {van Vollenhoven}, {Ronald F} and Theo Rispens and Maarten Boers and Wolbink, {Gerrit Jan}",

year = "2018",

month = oct,

doi = "https://doi.org/10.1136/annrheumdis-2017-212602",

language = "English",

volume = "77",

pages = "e68",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "10",

}

l'Ami, MJ, Krieckaert, CLM, Nurmohamed, MT , van Vollenhoven, RF , Rispens, T , Boers, M & Wolbink, GJ 2018, 'Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al', Annals of the rheumatic diseases, vol. 77, no. 10, e68, pp. e68. https://doi.org/10.1136/annrheumdis-2017-212602

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al. / l'Ami, Merel J; Krieckaert, Charlotte L M; Nurmohamed, Michael T et al.
In: Annals of the rheumatic diseases, Vol. 77, No. 10, e68, 10.2018, p. e68.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Response to

T2 - Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al

AU - l'Ami, Merel J

AU - Krieckaert, Charlotte L M

AU - Nurmohamed, Michael T

AU - van Vollenhoven, Ronald F

AU - Rispens, Theo

AU - Boers, Maarten

AU - Wolbink, Gerrit Jan

PY - 2018/10

Y1 - 2018/10

KW - Journal Article

U2 - https://doi.org/10.1136/annrheumdis-2017-212602

DO - https://doi.org/10.1136/annrheumdis-2017-212602

M3 - Comment/Letter to the editor

C2 - 29133475

SN - 0003-4967

VL - 77

SP - e68

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 10

M1 - e68

ER -

l'Ami MJ, Krieckaert CLM, Nurmohamed MT , van Vollenhoven RF , Rispens T , Boers M et al. Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al. Annals of the rheumatic diseases. 2018 Oct;77(10):e68. e68. Epub 2017 Nov 13. doi: https://doi.org/10.1136/annrheumdis-2017-212602